Clinical TrialAlcohol Use Disorder (AUD)LSDPlaceboPlaceboCompleted

Single Oral Lysergide (LSD 500 µg) in Inpatient Alcoholic Rehabilitation: Controlled Evaluation with Schizophrenic Sub-Analysis (Tomsovic & Edwards 1970)

This unregistered trial (n=75) was a partially randomised, placebo-controlled evaluation of a single 500 µg oral dose of LSD for alcohol use disorder in an inpatient rehabilitation setting, which found higher abstinence rates in non-schizophrenic participants at one year.

Ask Blossom about this trial
Target Enrollment
75 participants
Study Type
interventional
Design
Randomized, single Blind

Detailed Description

This synthetic trial has been added to our database because a psychedelic paper (about a clinical trial) references this trial, but no (live) registration can be found.

The study evaluated the efficacy of a single 500 µg oral dose of lysergide (LSD) administered within a 90-day inpatient alcoholic rehabilitation programme. Participants were assigned to either the lysergide arm, a placebo control group, or a group receiving routine programme care. The administration took place in a specially furnished room with music and colourful decor, accompanied by a non-directive nursing assistant and intermittent psychiatric visits.

Primary outcomes focused on drinking control measured via the Drinking Adjustment Scale at three, six, and twelve months, with validation from spouses and informants. The researchers conducted a sub-analysis comparing schizophrenic and non-schizophrenic participants. Results indicated that non-schizophrenic alcoholics experienced better reactions to the drug and demonstrated higher rates of abstinence at the one-year follow-up compared to both the schizophrenic subgroup and those treated through standard methods.

Study Arms & Interventions

Lysergide

experimental

Single oral dose of lysergide (LSD) in a specially furnished room as part of a 90-day rehabilitation program.

Interventions

  • LSD500 mcg
    via Oral• single dose• 1 doses total

    The study included both nonschizophrenic and schizophrenic subgroups.

Control Group I

placebo

Volunteers for the lysergide treatment who did not receive the drug or received a placebo substitute.

Interventions

  • Placebo
    via oral• single dose• 1 doses total

    Described as a volunteer control group that may have experienced a deprivation effect.

Control Group II

active comparator

Patients who passed through the regular 90-day Alcoholic Rehabilitation Program but did not volunteer for the lysergide project.

Interventions

  • Placebo

    Standard 90-day rehabilitation program participants.

Study Details

Related Publications

PaywallindividualPrimary

Lysergide Treatment of Schizophrenic and Nonschizophrenic Alcoholics; A Controlled Evaluation

This historic study (1970; n=75) used LSD (500μg) in the treatment of alcoholics and found that those without schizophrenia (about 2/3 of patients) responded better.

Published
Journal
Journal of Studies on Alcohol and Drugs
Authors
Tomsovic, M., Edwards, R. V.